Drug intelligence / Profile preview

MES-Fudan University-triple-negative breast cancer

Development stage: Unknown
Lead developer: Fudan University Shanghai Cancer Center
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

MES-Fudan University-triple-negative breast cancer refers to the therapeutic strategy and associated drug regimens for the Mesenchymal-like (MES) subtype of triple-negative breast cancer (TNBC) as defined in the FUTURE (Fudan University Triple-negative breast cancer Umbrella REsearch) trial (NCT03805399). Developed by Fudan University, this precision medicine approach stratifies MES-subtype patients based on PI3K/AKT pathway activation. Patients without PI3K/AKT activation are treated with a combination of famitinib (a multi-kinase inhibitor targeting VEGFR, PDGFR, and c-Kit) and etoposide (VP-16). Patients with PI3K/AKT activation receive an mTOR inhibitor (typically everolimus) in combination with nab-paclitaxel. The MES subtype is characterized by high expression of genes involved in the epithelial-mesenchymal transition and angiogenesis, which these regimens are designed to target.

Other names: MES Subtype Regimen (FUTURE Trial)FUSCC-TNBC MES Arm

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)Vascular niche (Vascular biology niche)TUBB (Tubulin (alpha and beta subunits))mTOR (Mammalian target of rapamycin kinase)PDGFR (PDGFR family)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on MES-Fudan University-triple-negative breast cancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MES-Fudan University-triple-negative breast cancer.

Explore the full profile